Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 4/20 | 0.56 |
| ▸ | ACE | P12821 | 5/20 | 0.52 |
| ▸ | CPA1 | P15085 | 3/20 | 0.51 |
| ▸ | ACE2 | Q9BYF1 | 3/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | FPR2 | P25090 | 1/20 | 0.50 |
| ▸ | ECE1 | P42892 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2740200 | 0.93 | MME (0.63) | MMEACECPA1ACE2NPSR1 | |
| SCHEMBL2739563 | 0.93 | MME (0.63) | MMEACECPA1ACE2NPSR1 | |
| SCHEMBL2739487 | 0.93 | MME (0.63) | MMEACECPA1ACE2NPSR1 | |
| SCHEMBL2739525 | 0.93 | MME (0.63) | MMEACECPA1ACE2NPSR1 | |
| Trifluoroacetic Acid SCHEMBL29484059 | 0.91 | PTPN1 (0.52) | — | |
| Trifluoroacetic Acid SCHEMBL29484051 | 0.87 | ALDH1A1 (0.58) | — | |
| Trifluoroacetic Acid SCHEMBL29617362 | 0.86 | NAALAD2 (0.60) | MMEACE | |
| SCHEMBL2739560 | 0.85 | FPR2 (0.55) | MMEACECPA1ACE2NPSR1 | |
| SCHEMBL825577 | 0.84 | MME (0.67) | MMEACECPA1ACE2NPSR1 | |
| SCHEMBL1329567 | 0.84 | MME (0.67) | MMEACECPA1ACE2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612429-B2 | Derivatives of dolaproine-dolaisoleuine peptides | AGENSYS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-20220204557-A1 | DERIVATIVES OF DOLAPROINE-DOLAISOLEUINE PEPTIDES | AGENSYS, INC. (US) | 2022-06-30 | — | — | US | disclosed |
| US-11312748-B2 | Derivatives of dolaproine-dolaisoleucine peptides | AGENSYS, INC. (US) | 2022-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204557-A1 | DERIVATIVES OF DOLAPROINE-DOLAISOLEUINE PEPTIDES | DDOST, VIP, THPO | MME 1043/4885ACE 1764/4885CPA1 941/4885 |
| US-12612429-B2 | Derivatives of dolaproine-dolaisoleuine peptides | DDOST, NGLY1, GRPR | MME 969/4885ACE 2286/4885CPA1 156/4885 |
| US-11312748-B2 | Derivatives of dolaproine-dolaisoleucine peptides | VIP, DDOST, DNPEP | MME 541/4885ACE 1878/4885CPA1 526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.